Search | Page 5 | Aplastic Anemia and MDS International Foundation


Search results

  1. Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia

    ... patients: Patients should have a diagnosis of AML ( de novo or transformed from hematologic malignancies). Patients with high-risk ...

    Clinical Trial last updated 05/23/2016 - 3:37pm.

  2. 8-Chloro-Adenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

    ... who have failed at least 1 line of salvage therapy De novo AML who have not achieved CR after 2 lines of therapy AML evolving ...

    Clinical Trial last updated 05/23/2016 - 3:25pm.

  3. A Trial to Evaluate Two Schedules of MS275 in Combination With 5AC in Elderly Patients With Acute Myeloid Leukemia (AML)

    ... One of the following: Untreated AML in ( de novo or treatment related) patients of age ≥ 60 years in the following ...

    Clinical Trial last updated 06/03/2016 - 3:09pm.

  4. Myeloablative Unrelated Donor Cord Blood Transplantation With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cells for Patients With High Risk Hematological Malignancies

    ... bone marrow , or aplasia post-therapy. This includes de novo acute leukemia or acute leukemia that is therapy related or arising ...

    Clinical Trial last updated 04/29/2016 - 1:33pm.